The role of pro-resolution lipid mediators in infectious disease

Immunology (Impact Factor: 3.74). 02/2014; 141(2):166-173. DOI: 10.1111/imm.12206
Source: PubMed

ABSTRACT Inflammation is an essential host defence against infection, but can be damaging when excessive. Resolution of inflammation is an active process, and the pro-resolution effects of lipoxins, resolvins and protectins have received significant interest. Here, we review emerging data on the role of these lipid mediators in infectious disease. Lipoxins influence host control of Mycobacterium tuberculosis, Toxoplasma gondii, Trypanosoma cruzi and Plasmodium berghei cerebral malaria in mice. Their effects are protective in toxoplasmosis, T. cruzi infection and cerebral malaria but detrimental in tuberculosis; related to the balance between pathogen-control and excessive immune response. Topical lipoxin abrogates the tissue damage seen in a rabbit model of Porphyromonas gingivalis periodontitis. The increased virulence of H5N1 influenza A virus in mice correlates with reduced expression of SOCS2, required to mediate the effects of lipoxin. Mice unable to synthesize lipoxin suffer increased lung pathology during respiratory syncytial virus infection. Protectin suppresses influenza A virus replication in vitro and increases survival in a mouse model of severe influenza infection. Resolvins were investigated in a number of animal models of systemic bacterial infection, and were found to enhance phagocytic clearance of bacteria, reduce inflammation severity, promote neutrophil apoptosis, modulate neutrophil chemotaxis and importantly, reduce mortality. Interestingly, resolvin also enhances the antibacterial effect of ciprofloxacin and vancomycin. Topical resolvin application reduces the severity of herpes simplex virus ocular infection in mice. If the effects of these mediators translate from pre-clinical studies into successful clinical trials, they represent promising new strategies in managing infectious disease.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The biosynthesis pathway of eicosanoids derived from arachidonic acid, such as prostaglandins and leukotrienes, relates to the pathophysiology of diabetes mellitus (DM). A better understanding of how lipid mediators modulate the inflammatory process may help recognize key factors underlying the progression of diabetes complications. Our review presents recent knowledge about eicosanoid synthesis and signaling in DM-related complications, and discusses eicosanoid-related target therapeutics.
    BioMed Research International 03/2015; DOI:10.1155/2015/568408 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza A viruses are the causative agents of seasonal and pandemic infections. Influenza strains have recently emerged that show resistance to anti-viral drugs. Moreover, therapies in critically ill patients with severe influenza are limited, with the current anti-viral drugs showing disappointing results even in the absence of obvious viral resistance. Given the high mortality associated with avian H5N1 or H7N9 infections and the risk of pandemic potentials, effective drugs are needed for the treatment of severe influenza. A virus-host interaction is a multidimensional host response, in which not only genes and protein but also metabolites are up- or down-regulated, and cellular pathways and networks implicated in the viral pathogenesis are perturbed. Thus, it seems an attractive strategy to overcome influenza by targeting host metabolites and/or metabolic pathways involved in viral pathogenesis. Using lipidomics and lipid libraries screening, potectin D1 isomer (PDX) derived from the 15-lipoxygenase product 17S-H(p)DHA and/or 17HDHA precursor, has recently been identified, which supresses influenza virus replication by inhibiting the nuclear export of viral mRNA rather than regulating resolution of inflammation. Contribution of the protectins to control influenza virus replication and their therapeutic potentials are reviewed here. This article is part of a Special Issue entitled "Oxygenated metabolism of PUFA: analysis and biological relevance". Copyright © 2015. Published by Elsevier B.V.
    Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 01/2015; DOI:10.1016/j.bbalip.2015.01.006 · 4.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Toxoplasmosis, an infectious and inflammatory syndrome, is one of the most important foodborne diseases causing hospitalization and death in U.S.A. Toxoplasma infects nucleated cells including pancreatic and destroys the β cells. Toxoplasma is a Category B classified infection by CDC and NIH, which once infected the organisms reside in tissues in cysts form for the host's lifelong awaiting reactivation. Congenital toxoplasmosis occurs by transplacental transmission during maternal infection or reactivation of organisms and manifests with spontaneous abortion, or severe physical and mental defects. Currently, there is no safe and effective therapeutic modality against congenital toxoplasmosis or the persistent chronic infection. Here, toxoplasmosis and possible involvement of infection in induction of pancreatitis, and an experimental drug efficacy is discussed.


Available from
May 26, 2014